Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Sun Pharma.Inds.
-
Master Rating:
-
Sun Pharm.Industries has an operating revenue of Rs. 36,704.43 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 5% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 47 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Sun Pharmaceuticals Industries Ltd Forecast
Price Estimates
Eps And Sales Estimates
Sun Pharmaceuticals Industries Ltd Synopsis
NSE-Medical-Generic Drugs
Sun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 12803.21 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2021. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.-
Market Cap
INR 183,849.03 Cr
-
Sales
INR 14,016.76 Cr
-
Shares in Float
110.37 Cr
-
No of Funds
824 K
-
Yield
0.98%
-
Book Value
7.34
-
U/D Vol Ratio
1.6
-
LTDebt/Equity
19%
-
Alpha
0.03
-
Beta
0.89
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% |
| Mutual Funds | 12.03% | 11.93% | 10.99% |
| Insurance Companies | 9.44% | 9.02% | 8.98% |
| Foreign Portfolio Investors | 11.5% | 11.67% | 12.19% |
| Financial Institutions/ Banks | 0.47% | 0.63% | 0.69% |
| Individual Investors | 7.22% | 7.34% | 7.2% |
| Others | 4.86% | 4.93% | 5.47% |
| Name | Designation |
|---|---|
| Mr. Israel Makov | Chairman |
| Mr. Dilip S Shanghvi | Managing Director |
| Mr. Sailesh T Desai | Whole Time Director |
| Mr. Kalyanasundaram Subramanian | Whole Time Director |
| Mr. Sudhir V Valia | Non Exe.Non Ind.Director |
| Dr. Pawan Goenka | Independent Director |
| Mr. Rama Bijapurkar | Independent Director |
| Ms. Rekha Sethi | Ind. Non-Executive Director |
| Mr. Vivek Chaand Sehgal | Ind. Non-Executive Director |
| Mr. Gautam Doshi | Ind. Non-Executive Director |
Sun Pharmaceuticals Industries Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 4143.15 | 3312.54 | 3119.04 | 3366.01 | 3207.24 |
| Operating Expenses Qtr Cr | 3278.88 | 2694.46 | 2479.39 | 2641.78 | 2505.02 |
| Operating Profit Qtr Cr | 864.27 | 631.49 | 680.25 | 746.24 | 787.49 |
| Depreciation Qtr Cr | 333.64 | 150.92 | 151.76 | 146.89 | 145.37 |
| Interest Qtr Cr | 103.98 | 105.72 | 102.73 | 71.93 | 13.42 |
| Tax Qtr Cr | -98.15 | 13.35 | 43.68 | -7.15 | -22.93 |
| Net Profit Qtr Cr | 809.07 | 419.3 | 327.39 | 555.55 | 724.81 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 12953.43 | 14042.85 | 11574.65 | 10134.29 | 8199.04 |
| Operating Expenses Annual Cr | 9867.21 | 9820.28 | 8546.95 | 8027.99 | 7569.99 |
| Operating Profit Annual in Cr | 2936 | 2711.65 | 1756.26 | 978.26 | 113.97 |
| Depreciation Cr | 586.81 | 561.56 | 552.95 | 487.24 | 422.28 |
| Interest Annual Cr | 256.98 | 408.01 | 540.92 | 388.31 | 223.57 |
| Tax Annual Cr | 13.17 | 41.86 | -97.15 | -25.39 | 6.04 |
| Net Profit Annual Cr | 2139.7 | 3211.14 | 816.6 | 305.64 | -22.84 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 1737.25 | 1305.85 | 1242.18 | -1171.23 | -1621 |
| Cash from Investing Activity Annual Cr | -601.8 | 1479.29 | 433.69 | 1391.62 | 2381.38 |
| Cash from Financing Annual Activity Cr | -1126.29 | -2871.15 | -1468.59 | -272.1 | -752.99 |
| Net Cash Flow Annual Cr | 9.16 | -86.01 | 207.28 | -51.71 | 7.39 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 25040.16 | 24396.22 | 22843.61 | 22322.61 | 21012.47 |
| Fixed Assets Annual Cr | 6007.15 | 5825.35 | 5620.96 | 5632.41 | 5139.13 |
| Total Non Current Assets Annual Cr | 26932.49 | 26469.21 | 26544.36 | 27216.6 | 27481.08 |
| Total Current Assets Annual Cr | 12066.34 | 11941.12 | 11169.77 | 9575.21 | 6388.19 |
| Total Assets Annual Cr | 38998.83 | 38410.33 | 37714.13 | 36791.81 | 33869.27 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 104.3644 | 101.6805 | 95.2094 | 93.038 | 87.5775 |
| ROE Annual % | 8.54 | 13.16 | 3.57 | 1.36 | -0.1 |
| ROCE Annual % | 8.15 | 13.45 | 10.12 | 6.68 | 0.9 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 24.1 | 33.69 | 29.38 | 23.38 | 8.18 |
Sun Pharmaceuticals Industries Ltd Technicals
EMA & SMA
CURRENT PRICE
766.25 
(2.8)
-
- Bullish Moving Averages 5
- Bearish Moving Averages 11
EMA
-
20 Day
780.3
-
50 Day
787.25
-
100 Day
767.66
-
200 Day
710.37
Sun Pharmaceuticals Industries Ltd Resistance and support
749.65 PIVOT
-
First Resistance
758.95
-
Second Resistance
772.55
-
Third Resistance
781.85
-
First Support
736.05
-
Second Support
726.75
-
Third Support
713.15
-
RSI
43.04
-
MFI
32.22
-
MACD
-12.98
-
MACD signal line
-9.28
Sun Pharmaceuticals Industries Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 5,417,545 | 246,227,420 | 45.45% |
| Week | 5,067,917 | 237,127,836 | 46.79% |
| 1 Month | 3,493,301 | 164,045,399 | 46.96% |
| 6 Month | 4,268,453 | 172,915,051 | 40.51% |
Sun Pharmaceuticals Industries Ltd Price change analysis
-49.15
Over 1 month
Low High 740.1 822
-23.7
Over 3 month
Low High 740.1 851
88.8
Over 6 months
Low High 652.7 851
221.6
Over Year
Low High 539.45 851Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Ipca Laboratories Ltd | 2,767.10 | 2,051.15 (-0.76%) | 6698 |
| Alkem Laboratories Ltd | 4,067.70 | 3,468.25 (0.83%) | 5317 |
| Sharon Bio-Medicine Ltd | 3.30 | 3.26 (0.00%) | 32550 |
| Suven Life Sciences Ltd | 124.40 | 91.30 (2.35%) | 23877 |
News
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details Read More
Sun Pharmaceutical Industries Ltd - 524715 - Intimation Abou
As per Letter attached Read More
Sun Pharmaceutical Industries Ltd - 524715 - Disclosures und
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg
As per Letter attached Read More
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement u
Intimation of Schedule of Analyst / Institutional Investor Meeting Read MoreBlogs